|
The Bing Center for Waldenstrom's Research at the Dana-Farber Cancer Institute is
committed to providing comprehensive state-of-the-art treatment for Waldenstrom's Macroglobulinemia,
including novel therapeutics, combination therapies, and immunotherapies. Our clinical trials are
devoted to advancing the effectiveness of current treatment options for Waldenstrom's, while ensuring
the highest standard of care.
One of our priorities is maintaining active clinical trials year round in an effort to constantly
improve our understanding and continue to offer patients the most effective treatments for
Waldenstrom's macroglobulinemia. All of our clinical trials are open through the Waldenstrom's Macroglobulinemia Clinical Trials Group,
which is composed of over 20 major cancer centers around the world. By maintaining such an
extensive contingent of collaborating centers, we hope to be better able to enroll patients
in our trials without delay. Not only does the WMCTG allow more convenient patient access to
treatment, but will also facilitate completion of clinical trials in a more timely manner.
New clinical trials are initiated only after drugs and other active agents are carefully
screened through basic research studies and/or
other successful experiences in other patient populations. The goals of all our clinical
trials include increasing the number of patients entering into remissions, particularly complete
remissions, as well as increasing the duration of these remissions.
All of our proposed clinical trials are approved by a Scientific Review Committee (SRC) and an
Institutional Review Board (IRB) and are regulated through the Office For The Protection Of
Research Subjects (OPRS) at the Dana-Farber Cancer Institute. The IRB serves to ensure that
our trials comply with existing regulations of the FDA, Department of Health and Human Services
(HHS) and the state's DPH for the protection of human subjects.
If you are interested in more information in either participating in a clinical trial or becoming
a co-investigator on one of our trials, please contact either:
|
